IMGN151 alone or with carboplatin, olaparib, or bevacizumab for adults with high-grade serous gynecologic cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, multi-center trial plans to enroll about 377 adults with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer into four treatment arms. Participants receive intravenous IMGN151 as monotherapy or combined with carboplatin, olaparib, or bevacizumab, administered in repeated treatment cycles. The study tracks changes in disease activity (using RECIST v1.1 for most participants), adverse events, and tolerability. Enrollment requires ECOG performance status 0–1 and adherence to timing rules after prior therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ECOG performance status of 0 or 1
* Participants (except for platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer (PSOC) participants without disease progression after platinum combination standard of care therapy in Arms B and D) will have ≥ 1 lesion that meets the definition of measurable disease by RECIST v1.1 (radiographically measured by the investigator).
* Participants will have high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC).
* Participant has completed prior therapy within the specified times below:

  * Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of IMGN151.
  * Focal radiation completed ≥ 2 weeks prior to the first dose of study treatment.

Exclusion Criteria:

* Participants with ovarian cancer with histologies including: endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, as well a low-grade or borderline ovarian tumor.
* History of clinically significant medical conditions or any other reason that the investigator determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study treatment.
* Prior treatment with FRα-targeting therapy.
* Prior wide-field radiotherapy affecting more than 20% of the bone marrow.

Where it's running

• Start Los Angeles /ID# 281533
  Los Angeles, California, United States Recruiting
• University of Colorado Hospital- Aurora /ID# 278232
  Aurora, Colorado, United States Recruiting
• University Of Minnesota /ID# 277850
  Minneapolis, Minnesota, United States Recruiting
• Holy Name Medical Center /ID# 279017
  Teaneck, New Jersey, United States Recruiting
• SUNY Upstate Medical University - Syracuse /ID# 277305
  Syracuse, New York, United States Recruiting
• University of Cincinnati Medical Center. /ID# 278925
  Cincinnati, Ohio, United States Recruiting

Study contacts

• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Romiplostim N01 plus ATRA for persistent chemotherapy-induced low platelets after remission from gynecologic, breast, or lung cancer

  This trial tests whether adding ATRA to Romiplostim N01 helps people keep a safe platelet count after finishing chemotherapy for certain cancers.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07586826

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Immunonutrition and Brain Monitoring to See if Delirium Happens After Gynecologic Cancer Surgery

  This study tests whether a preoperative immunonutrition scoring plus intraoperative brain monitoring can help predict or relate to postoperative delirium in women aged 65 and older undergoing major gynecologic cancer surgery.

  Recruiting Elazıg Fethi Sekin Sehir Hastanesi · Elâzığ, Elâzığ · NCT07877285

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Raludotatug Deruxtecan with or without Bevacizumab for advanced ovarian, peritoneal, or fallopian tube cancer

  This trial tests whether adding raludotatug deruxtecan (R-DXd) to or without bevacizumab helps people with advanced ovarian cancer that progressed after PARP-inhibitor maintenance.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Fountain Valley, California and 6 other locations · NCT07743164

• Prophylactic subcutaneous drainage after gynecologic cancer surgery

  This study tests whether placing a small drain under the skin after gynecologic cancer surgery helps prevent wound problems in women with thicker tissue under the skin.

  Recruiting Başakşehir Çam & Sakura City Hospital · Istanbul · NCT07735962

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.